CYP1B1 and prostate carcinoma: Likewise, studies on other cancers, such as in prostate cancer, Pastina et al., (2010) found a significant association between CYP1B1 4326 GG genotype with non-response to the docetaxel (26.1% vs 73.9%, p=0.014) compared to CYP1B1 4326 CC and CG genotypes.